US-based pharmaceutical giant Allergan has reportedly formally rejected an acquisition bid of nearly $50 billion for the company, proposed by Canadian peer Valeant Pharmaceuticals.
According to reports, Allegan shot down the offer because it “substantially undervalues Allergan, creates significant risks and uncertainties for the stockholders of Allergan, and is not in …read more
Source: Global Competition Law Blogs